KyungHae Jung

26PUBLICATIONS
162CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersClinical midwiferyFrench language
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jun 08, 2026
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.

|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Apr 01, 2026
A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer.

Shinyoung Lee, Hyehyun Jeong, Yeokyeong Shin

|Mar 31, 2026
Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy.

Minseung Suh, Jeongryul Ryu, Hojin Song

|Sep 29, 2025
Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy in De Novo Stage IV Breast Cancer Patients.

Haena Shin, Sei-Hyun Ahn, Sae Byul Lee

|Aug 20, 2025
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer.

Seung Hyuck Jeon, Koung Jin Suh, Sungmin Jung

Pageof 5

Frequent Collaborators

8 joint publications

Jae Ho Jung

6 joint publications

Sung-Bae Kim

6 joint publications

Jong Won Lee

5 joint publications

Young Ho Yun